Anti-infective agents in medicinal chemistry最新文献_第3页

Current Understanding of Polymyxin B Applications in Bacteraemia/ Sepsis Therapy Prevention: Clinical, Pharmaceutical, Structural and Mechanistic Aspects 多粘菌素B在预防菌血症/败血症治疗中的应用现状:临床、药物、结构和机制方面

Anti-infective agents in medicinal chemistry Pub Date : 2009-09-30 DOI: 10.2174/187152109789760171

P. Garidel, K. Brandenburg, Martin-Luther-Universität Halle-Wittenberg, Physikalische Chemie

{"title":"Current Understanding of Polymyxin B Applications in Bacteraemia/ Sepsis Therapy Prevention: Clinical, Pharmaceutical, Structural and Mechanistic Aspects","authors":"P. Garidel, K. Brandenburg, Martin-Luther-Universität Halle-Wittenberg, Physikalische Chemie","doi":"10.2174/187152109789760171","DOIUrl":"https://doi.org/10.2174/187152109789760171","url":null,"abstract":"Polymyxin B (PMB) belongs to a class of antibiotics discovered more than six decades ago. PMB was used for various bacterial infection threatening, in particular to sepsis. Its use, however, was abandoned because of the observation of severe side effects. In the last years this view changed due to the appearance of multi-drug resistant Gram-negative pathogens, which were resistant to most available antibiotics, leading to a re-evaluation of the polymyxin antibiotics (PMB and PME). Although there is a large market potential for the development of drugs to fight sepsis, the available successful clinical strategies are very limited. The cause for this lies in the clinical failures of a number of drug candidates, which were tested in the last years. This was attributed to some extent to our elementary understanding of the pathophysiology of sepsis, to not optimally designed clinical trials and a lack of appropriate pre-clinical models to establish the proof of concept (POC). At that time there were just humble knowledge about the structural mechanisms involved in the advantageous aspects of PMB-endotoxin interactions to increase the knowledges outcome in sepsis therapy. Therefore, the current paper describes the clinical aspects of PMB application in bacteraemia and sepsis therapy. How- ever, the focus of the presented paper lies in the structural and mechanistic aspects of PMB-endotoxin (LPS: lipopolysac- charide) recognition and how this knowledge can be applied for the development or improvement of new clinical drug candidates to support sepsis therapies. Due to chemical similarities between PME and PMB, certain aspects of the use of PME as an antimicrobial agent and in sepsis therapy are considered and compared to PMB.","PeriodicalId":89320,"journal":{"name":"Anti-infective agents in medicinal chemistry","volume":"115 1","pages":"367-385"},"PeriodicalIF":0.0,"publicationDate":"2009-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/187152109789760171","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68023339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 32

Antiprotozoal Agents: An Overview 抗原虫制剂:综述

Anti-infective agents in medicinal chemistry Pub Date : 2009-09-30 DOI: 10.2174/187152109789760199

Cedric S. Graebin, F. Uchôa, Lilian S C Bernardes, V. L. Campo, I. Carvalho, V. Eifler-Lima

{"title":"Antiprotozoal Agents: An Overview","authors":"Cedric S. Graebin, F. Uchôa, Lilian S C Bernardes, V. L. Campo, I. Carvalho, V. Eifler-Lima","doi":"10.2174/187152109789760199","DOIUrl":"https://doi.org/10.2174/187152109789760199","url":null,"abstract":"The therapy of parasitic diseases has relied, until recently, on the use of a very limited number of drugs, most of them of low efficacy, leading to side effects and in certain cases with high toxicity. This review focuses on the chemother- apy to treat diseases caused by Trypanosoma cruzi (Chagas' disease), Trypanosoma b. gambiense and Trypanosoma b. rhodesiense (sleeping sickness), Plasmodium (malaria) and Leishmania (leishmaniasis). Therefore, we will summarize drugs currently available and future specific chemotherapy against these neglected diseases under clinical evaluation. The most advanced antichagasic candidates are represented by posaconazole, TAK-187 and albaconazole, which have com- pleted their pre-clinical development as anti-T. cruzi agents, while new quinines concerning to ferroquine, tafenoquine and AQ-13 are in phase I or II of clinical trials as promising candidates for the treatment of malaria. Although parafuramidine has been under phase III clinical trials to treat Human African Trypanosomiasis (HAT), its development was discontinued due to liver problems. Finally, new approaches for the treatment of leishmaniasis were achieved by using miltefosine and, more recently, the aminoglycoside paromomycin, which was approved after clinical trials and, owing to its milder adverse effects and low cost, is being considered as a potential first-choice treatment for the disease. Thus, this review aims to highlight the available drugs to treat four endemic parasitic diseases, as well as promising therapeutic approaches and their corresponding targets under development, but it is not intended to be an exhaustive survey on the subject.","PeriodicalId":89320,"journal":{"name":"Anti-infective agents in medicinal chemistry","volume":"43 1","pages":"345-366"},"PeriodicalIF":0.0,"publicationDate":"2009-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/187152109789760199","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68023350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 31

Peptidomimetics and their Applications in Antifungal Drug Design 拟肽物及其在抗真菌药物设计中的应用

Anti-infective agents in medicinal chemistry Pub Date : 2009-09-30 DOI: 10.2174/187152109789760216

S. Moradi, Saeed Soltani, Alireza Madjid Ansari, S. Sardari

引用次数: 21

Plant Natural Products as a Potential Source for Antibacterial Agents: Recent Trends 植物天然产物作为抗菌药物的潜在来源:最新趋势

Anti-infective agents in medicinal chemistry Pub Date : 2009-06-30 DOI: 10.2174/187152109788680199

M. Shahid, A. Shahzad, F. Sobia, Aastha Sahai, T. Tripathi, Anuradha Singh, H. Khan, Umesh

引用次数: 33

Sterols and Triterpenoids with Antiviral Activity 具有抗病毒活性的甾醇和三萜

Anti-infective agents in medicinal chemistry Pub Date : 2009-06-30 DOI: 10.2174/187152109788680207

T. Řezanka, L. Siříšťová, K. Sigler

引用次数: 23

Malaria and Leishmaniasis: Current Status of Chemotherapy, New Leads and Targets for Drug Discovery 疟疾和利什曼病:化疗的现状，药物发现的新线索和靶点

Anti-infective agents in medicinal chemistry Pub Date : 2009-06-30 DOI: 10.2174/187152109788680216

R. Batra

引用次数: 6

Antiviral Sesqui-, Di- and Sesterterpenes 抗病毒倍半萜、二萜和倍半萜

Anti-infective agents in medicinal chemistry Pub Date : 2009-06-30 DOI: 10.2174/187152109788680225

T. Řezanka, L. Siříšťová, K. Sigler

引用次数: 2

Interaction between Phenols and Bovine Serum Albumin 酚类物质与牛血清白蛋白的相互作用

Anti-infective agents in medicinal chemistry Pub Date : 2009-06-30 DOI: 10.2174/187152109788680234

Yuan-Zhi Song, Jimin Xie, Yunlong Wu, Min Chen, Ganqing Zhao, Lv Xiaomeng, Huoming Shu, Songtao Chen

引用次数: 0

The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases. TRAIL的生物学和基于TRAIL的治疗方法在感染性疾病中的作用。

Anti-infective agents in medicinal chemistry Pub Date : 2009-04-01 DOI: 10.2174/187152109787846060

Brett D Shepard, Andrew D Badley

引用次数: 0

Antiviral Therapy of Chronic Hepatitis B with Nucleotide Analogs 核苷酸类似物抗病毒治疗慢性乙型肝炎

Anti-infective agents in medicinal chemistry Pub Date : 2009-03-31 DOI: 10.2174/187152109787846079

Zhihua Liu, H. Cao, Jing Hu

引用次数: 1